Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

CARDIOPHARMA ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1000.0 Bankruptcy Risk  2018 2019/4 2019 2020/4 2020 2021/4 2021 2022/4 2022 2023/4 2023 2024/4 2024e N/A 2025e N/A Bankruptcy risk for industry   1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2%   Bankruptcy risk   1.1% 1.0% 0.9% 0.8% 0.7% 0.9% 7.1% 7.1%   Credit score (0-100)   87 89 90 91 95 89 34 34   Credit rating   A A A AA AA A BBB BBB   Credit limit (kDKK)   1,190.6 1,914.0 2,411.7 2,585.7 2,732.5 2,382.5 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2019/4 2019 2020/4 2020 2021/4 2021 2022/4 2022 2023/4 2023 2024/4 2024e N/A 2025e N/A Net sales   1,758 2,397 811 3,438 438 2,618 2,618 2,618   Gross profit   1,758 2,397 811 3,438 438 2,618 0.0 0.0   EBITDA   1,661 2,097 704 3,185 348 2,556 0.0 0.0   EBIT   1,661 2,097 704 3,185 348 2,556 0.0 0.0   Pre-tax profit (PTP)   1,753.6 1,578.4 4,280.0 2,902.5 1,022.2 2,910.6 0.0 0.0   Net earnings   1,728.6 1,574.6 4,278.6 2,900.7 1,018.6 2,910.3 0.0 0.0   Pre-tax profit without non-rec. items   1,754 1,578 4,280 2,903 1,022 2,911 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2019/4 2019 2020/4 2020 2021/4 2021 2022/4 2022 2023/4 2023 2024/4 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   25,027 26,202 30,081 27,981 28,000 28,260 26,410 26,410   Interest-bearing liabilities   1.6 1.7 1.7 50.0 0.0 0.7 0.0 0.0   Balance sheet total (assets)   25,071 26,248 30,125 28,073 28,122 28,303 26,410 26,410   Net Debt   -12,004 -13,731 -13,249 -6,642 -5,737 -5,017 -26,410 -26,410     See the entire balance sheet 1000.0 Volume  2018 2019/4 2019 2020/4 2020 2021/4 2021 2022/4 2022 2023/4 2023 2024/4 2024e N/A 2025e N/A Net sales   1,758 2,397 811 3,438 438 2,618 2,618 2,618   Net sales growth   4,890.6% 36.3% -66.2% 323.9% -87.3% 497.8% 0.0% 0.0%   Gross profit   1,758 2,397 811 3,438 438 2,618 0.0 0.0   Gross profit growth   4,890.6% 36.3% -66.2% 323.9% -87.3% 497.8% -100.0% 0.0%   Employees   0 0 0 0 0 0 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   25,071 26,248 30,125 28,073 28,122 28,303 26,410 26,410   Balance sheet change%   3.0% 4.7% 14.8% -6.8% 0.2% 0.6% -6.7% 0.0%   Added value   1,661.4 2,097.1 704.0 3,185.4 347.8 2,556.4 0.0 0.0   Added value %   94.5% 87.5% 86.8% 92.6% 79.4% 97.6% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   1.0 2.0 -1.0 1.0 -1.0 1.0 0.0 0.0   EBIT trend   1.0 2.0 3.0 4.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2018 2019/4 2019 2020/4 2020 2021/4 2021 2022/4 2022 2023/4 2023 2024/4 2024e N/A 2025e N/A EBITDA %   94.5% 87.5% 86.8% 92.6% 79.4% 97.6% 0.0% 0.0%   EBIT %   94.5% 87.5% 86.8% 92.6% 79.4% 97.6% 0.0% 0.0%   EBIT to gross profit (%)   94.5% 87.5% 86.8% 92.6% 79.4% 97.6% 0.0% 0.0%   Net Earnings %   98.3% 65.7% 527.4% 84.4% 232.6% 111.2% 0.0% 0.0%   Profit before depreciation and extraordinary items %   98.3% 65.7% 527.4% 84.4% 232.6% 111.2% 0.0% 0.0%   Pre tax profit less extraordinaries %   99.8% 65.9% 527.6% 84.4% 233.4% 111.2% 0.0% 0.0%   ROA %   8.3% 9.9% 15.7% 12.0% 3.6% 11.6% 0.0% 0.0%   ROI %   8.3% 9.9% 15.8% 12.0% 3.7% 11.6% 0.0% 0.0%   ROE %   7.0% 6.1% 15.2% 10.0% 3.6% 10.3% 0.0% 0.0%   1000.0 Solidity  2018 2019/4 2019 2020/4 2020 2021/4 2021 2022/4 2022 2023/4 2023 2024/4 2024e N/A 2025e N/A Equity ratio %   99.8% 99.8% 99.9% 99.7% 99.6% 99.8% 100.0% 100.0%   Relative indebtedness %   2.5% 1.9% 5.4% 2.7% 27.9% 1.6% 0.0% 0.0%   Relative net indebtedness %   -680.5% -571.1% -1,628.0% -191.9% -1,282.2% -190.0% -1,008.7% -1,008.7%   Net int. bear. debt to EBITDA, %   -722.6% -654.8% -1,881.8% -208.5% -1,649.5% -196.2% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 0.2% 0.0% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   19,465.9% 58,366.0% 9,212.6% 2,248.7% 11.5% 98,105.0% 0.0% 0.0%   1000.0 Liquidity  2018 2019/4 2019 2020/4 2020 2021/4 2021 2022/4 2022 2023/4 2023 2024/4 2024e N/A 2025e N/A Quick Ratio   277.4 302.5 303.3 73.5 47.6 118.9 0.0 0.0   Current Ratio   277.4 302.5 303.3 73.5 47.6 118.9 0.0 0.0   Cash and cash equivalent   12,006.1 13,732.7 13,250.2 6,691.7 5,737.4 5,017.5 0.0 0.0   1000.0 Capital use efficiency  2018 2019/4 2019 2020/4 2020 2021/4 2021 2022/4 2022 2023/4 2023 2024/4 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   688.0% 577.2% 1,640.9% 196.6% 1,325.2% 194.0% 1,008.7% 1,008.7%   Net working capital   521.1 5,299.2 684.6 1,252.9 2,104.6 1,280.1 0.0 0.0   Net working capital %   29.6% 221.1% 84.4% 36.4% 480.6% 48.9% 0.0% 0.0%   1000.0 Employee efficiency  2018 2019/4 2019 2020/4 2020 2021/4 2021 2022/4 2022 2023/4 2023 2024/4 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 0 0 0   EBIT / employee   0 0 0 0 0 0 0 0   Net earnings / employee   0 0 0 0 0 0 0 0